The British Liver Trust has accused the government of reneging on its pledge to introduce specialist liver scans to its community diagnostic centres (CDCs) in England.
The original announcement about the rollout of fibroscans to 100 CDCs by March 2025 was made by Health Minister Helen Whateley in a letter to the trust in March this year.1 This was confirmed by Health Minister Will Quince in a Westminster Hall debate on fatty liver disease in June.
The trust had described the move as a “ray of hope,” as the non-invasive scans have proven to be a gamechanger for early detection of liver disease. Traditionally, liver changes are initially picked up by ultrasound.
Currently there are 10 fibroscans in use in CDCs. They use a combination of an elastic …
Charity urges people in the east of England to write to their MP to overturn Government U-Turn on early detection of liver disease yourthurrock.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yourthurrock.com Daily Mail and Mail on Sunday newspapers.
<p style="text-align:justify"><strong>(16 October 2023, Copenhagen, Denmark) A groundbreaking new study, presented today at UEG Week 2023, has discovered a significant connection between birthweight and the onset of nonalcoholic fatty liver disease , now known as metabolic dysfunction-associated steatotic liver disease (MASLD), in young people.<sup>1</sup> Most notably, babies with a low birthweight were found to be four times more likely to develop MASLD in childhood, adolescence or young adulthood.<sup>1</sup></strong></p>
Researchers say findings provide further evidence for why it is so important to take steps during pregnancy to ensure the baby is born at a normal weight
Manuel Romero-Gómez and colleagues discuss how diet and modifiable factors can help prevent of non-alcoholic fatty liver disease and the importance of engaging all society through awareness, education, and policy change
### Key messages
Non-alcoholic fatty liver disease (NAFLD) is characterised by fat accumulation in hepatocytes in people who drink little or no alcohol and is strongly related to metabolic disorders like obesity, type 2 diabetes, dyslipidaemia, and arterial hypertension.1 The global prevalence of NAFLD has increased over time, now reaching more than 30% of the general adult population, with an estimated annual growth of 0.7%.2 NAFLD is a complex, heterogeneous, and dynamic disease, and progression to fibrosis (scarring of the liver) occurs in around 10-15% of patients with NAFLD.3 NAFLD is one of the main risk factors for developing liver cancer, which represents the third highest cause of death by cancer in the latest Globocan report.4
People with obesity are 3.5 t